Amanote Research
Register
Sign In
P3.01-68 Early SBRT to the Primary Tumor May Overcome the Icotinib Resistance in Patients With Advanced NSCLC Harboring EGFR Mutations
Journal of Thoracic Oncology
- United States
doi 10.1016/j.jtho.2018.08.1628
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Oncology
Respiratory Medicine
Pulmonary
Date
October 1, 2018
Authors
D. Lv
W. Wang
J. Ding
X. Wu
C. Zhou
B. Wang
F. Kong
H. Yang
Publisher
Elsevier BV
Related search
P3.01-54 a Historical Comparison of Patients With Advanced NSCLC Harboring Uncommon EGFR Mutations Before and After the Approval of Afatinib in Japan
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-80 Retrospective Analysis of the Impact of EGFR T790M Mutation Detection by Re-Biopsy in Patients With NSCLC Harboring EGFR Mutations.
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-111 Efficacy and Safety of Cytotoxic Drug Chemotherapy After First-Line EGFR-TKI in Elderly Patients With NSCLC Harboring Sensitive EGFR Mutations
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P2.03-10 Gene Mutational Profiling of Chinese TKI-Sensitizing EGFR Mutations NSCLC Patients Required Resistance to Icotinib Using NGS
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
MA15.10 Loss of T790M Mutation Is Associated With Early Progression to Osimertinib in Chinese Advanced NSCLC Patients Harboring EGFR T790M
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-85 Real-World Gefitinib 1st Line Treatment of Patients With Advanced NSCLC and EGFR Mutations - Serbian Single Center Experience
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P3.01-58 Relative Abundance of EGFR Mutations in Plasma Predicts Tumor Response to EGFR-TKI in Advanced Lung Adenocacarcinoma
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
P1.01-92 a Phase II Study of Afatinib Treatment for Elderly Patients With Previously Untreated Advanced NSCLC Harboring EGFR Mutations
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Afatinib in Locally Advanced/Metastatic NSCLC Harboring Common EGFR Mutations, After Chemotherapy: A Phase IV Study
Lung Cancer Management